Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1998-1-16
|
pubmed:abstractText |
The ratio of free prostate-specific antigen (f-PSA) to total PSA (t-PSA) in serum, calculated as percent free PSA (f-PSA%), is lower in patients with prostate carcinoma (PCa) than in patients with benign prostate hyperplasia (BPH). This parameter facilitates discrimination between the 2 groups of patients, but there is an overlapping of data. A better understanding of factors influencing this ratio is of practical importance. Therefore, f-PSA% was measured in controls and patients suffering from BPH, PCa and chronic prostatic inflammation with t-PSA concentrations up to 20 microg/l using the IMMULITE assays. The relationships of f-PSA% to clinical situation, age, prostate volume, kind of treatment, and stage and grade of tumor were calculated. Compared with controls or BPH patients, mean f-PSA% values were reduced in PCa patients and in patients with chronic prostatic inflammation. The prostate volume was the most important factor to influence f-PSA%. The difference of f-PSA% between PCa and BPH patients with prostate volumes smaller than 40 cm3 was lost if the prostate volumes exceeded 40 cm3. No relationship of f-PSA% to pTNM stage or grade of tumor was observed. In contrast to t-PSA concentrations, the f-PSA% values were not age-dependent and were not influenced by any kind of treatment in BPH and PCa patients either, which simplifies the use of f-PSA% compared with t-PSA. Thus, for using f-PSA% in clinical practice and for interpreting the data correctly, the advantages shown have to be considered along with the potential limitations of f-PSA%.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
19
|
pubmed:volume |
74
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
630-6
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:9421361-Adult,
pubmed-meshheading:9421361-Aged,
pubmed-meshheading:9421361-Aged, 80 and over,
pubmed-meshheading:9421361-Aging,
pubmed-meshheading:9421361-Enzyme Inhibitors,
pubmed-meshheading:9421361-Finasteride,
pubmed-meshheading:9421361-Humans,
pubmed-meshheading:9421361-Male,
pubmed-meshheading:9421361-Middle Aged,
pubmed-meshheading:9421361-Organ Size,
pubmed-meshheading:9421361-Prostate,
pubmed-meshheading:9421361-Prostate-Specific Antigen,
pubmed-meshheading:9421361-Prostatic Diseases,
pubmed-meshheading:9421361-Protein Binding,
pubmed-meshheading:9421361-Reference Values,
pubmed-meshheading:9421361-alpha 1-Antichymotrypsin
|
pubmed:year |
1997
|
pubmed:articleTitle |
Factors influencing the ratio of free to total prostate-specific antigen in serum.
|
pubmed:affiliation |
Department of Urology, University Hospital Charité, Humboldt University, Berlin, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|